Scheinberg M - Search Results

1

Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice.

Scheinberg M, Castañeda-Hernández G. Scheinberg M, et al. Arthritis Res Ther. 2014 Dec 6;16(6):501. doi: 10.1186/s13075-014-0501-5. Arthritis Res Ther. 2014. PMID: 25677586 Free PMC article. Review.

2

Scheinberg M, Pineda C, Castañeda-Hernández G, Zarbá JJ, Damião A, Arantes LH Jr, Jacobs I. Scheinberg M, et al. MAbs. 2018 Aug/Sep;10(6):827-842. doi: 10.1080/19420862.2018.1484977. Epub 2018 Aug 29. MAbs. 2018. PMID: 30156950 Free PMC article. Review.

3

Variability of intended copies for etanercept (Enbrel®): Data on multiple batches of seven products.

Hassett B, Scheinberg M, Castañeda-Hernández G, Li M, Rao URK, Singh E, Mahgoub E, Coindreau J, O'Brien J, Vicik SM, Fitzpatrick B. Hassett B, et al. Among authors: scheinberg m. MAbs. 2018 Jan;10(1):166-176. doi: 10.1080/19420862.2017.1387346. Epub 2017 Nov 7. MAbs. 2018. PMID: 29020508 Free PMC article.

4

Biosimilars in rheumatology: what the clinician should know.

Castañeda-Hernández G, González-Ramírez R, Kay J, Scheinberg MA. Castañeda-Hernández G, et al. RMD Open. 2015 May 23;1(1):e000010. doi: 10.1136/rmdopen-2014-000010. eCollection 2015. RMD Open. 2015. PMID: 26509046 Free PMC article.

5

The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review.

Grinblat B, Scheinberg M. Grinblat B, et al. Among authors: scheinberg m. Semin Arthritis Rheum. 2008 Feb;37(4):251-5. doi: 10.1016/j.semarthrit.2007.05.004. Epub 2007 Jul 20. Semin Arthritis Rheum. 2008. PMID: 17640718 Review.

6

Yellow fever revaccination during infliximab therapy.

Scheinberg M, Guedes-Barbosa LS, Mangueira C, Rosseto EA, Mota L, Oliveira AC, Lima RA. Scheinberg M, et al. Arthritis Care Res (Hoboken). 2010 Jun;62(6):896-8. doi: 10.1002/acr.20045. Arthritis Care Res (Hoboken). 2010. PMID: 20535801 Free article. Clinical Trial. No abstract available.

7

The appearance of pustular psoriasis during antitumor necrosis factor therapy.

Goncalves DP, Laurindo I, Scheinberg MA. Goncalves DP, et al. J Clin Rheumatol. 2006 Oct;12(5):262. doi: 10.1097/01.rhu.0000240045.16855.39. J Clin Rheumatol. 2006. PMID: 17023816 No abstract available.

8

The future landscape of biosimilars in rheumatology: Where we are where we are going.

Scheinberg M, Azevedo V. Scheinberg M, et al. Autoimmun Rev. 2019 Feb;18(2):203-208. doi: 10.1016/j.autrev.2018.09.005. Epub 2018 Dec 18. Autoimmun Rev. 2019. PMID: 30572130 Review.

9

The advent of biosimilar therapies in rheumatology--"O brave new world".

Scheinberg MA, Kay J. Scheinberg MA, et al. Nat Rev Rheumatol. 2012 Jun 5;8(7):430-6. doi: 10.1038/nrrheum.2012.84. Nat Rev Rheumatol. 2012. PMID: 22664834 Review.

10

Difference between Enbrel and Benepali treatment groups in 'hepatobiliary disorders'.

Scheinberg M, Azevedo V. Scheinberg M, et al. Ann Rheum Dis. 2016 Oct;75(10):e64. doi: 10.1136/annrheumdis-2016-210101. Epub 2016 Jul 18. Ann Rheum Dis. 2016. PMID: 27432354 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

240 results

Search Page